Destiny Pharma PLC
("Destiny" or "the Company")
Destiny Pharma to Participate in Panel Discussion at the
7th Annual LSX World Congress 2021
Brighton, UK, 2 February 2021 - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that Neil Clark, Chief Executive Officer, will be taking part in a panel discussion at the 7th Annual LSX World Congress to be held virtually between 1-5 February, 2021.
The panel discussion 'Investing In Infectious Disease - How Will The Covid Pandemic Transform The Development, Commercialisation, And Partnering Landscape?' will be held at 15:00 GMT on 2nd February 2021.
The panel will be made available through the conference website and will be available to registered participants throughout the event - www.lsxleaders.com/lsx-world-congress.
- Ends -
Enquiries:
Destiny Pharma plc
+44 (0) 1273 704 440
Neil Clark (Chief Executive Officer)
Shaun Claydon (Chief Financial Officer and Company Secretary)
finnCap Limited - Nominated Adviser and Joint Broker
+44 (0) 20 7220 0500
Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)
Alice Lane (ECM)
WG Partners LLP - Joint Broker
+44 (0) 20 3705 9330
Nigel Barnes / Claes Spång / Nigel Birks / Andrew Craig
Optimum Strategic Communication
+44 (0) 203 174 1789
Mary Clark / Shabnam Bashir / Manel Mateus
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
For further information, please visit https://www.destinypharma.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
